Merck is growing pharma sales and expanding margins, led by strong KEYTRUDA performance and cost discipline. Read more about ...

We recently published a list of 10 Best Pharma Stocks to Buy for Long Term Growth. In this article, we are going to take a ...

Merck & Co.'s peptides could be undergoing a transformation into oral tablets thanks to a $493 million licensing deal the ...

Merck signs deal with Austria's Cyprumed to develop oral peptide therapies, potentially paying up to $493 million for access ...

U.S. tariffs on pharmaceuticals could eventually mean higher prices for brand-name medicines, but in the near term the costs ...

The pharmaceutical industry faces environmental challenges. Green chemistry offers sustainable solutions to reduce waste and enhance drug discovery processes.

given his excellent track-record of licensing and royalty deals in multiple pharmaceuticals products, including pembrolizumab, now marketed as Keytruda by Merck. We will maximise shareholder value ...

Germany's Merck KGaA has said it needs to double the productivity of its R&D operations, with the aim of launching a new product every 18 months on average, to boost its pharma business.

The 21st century pharmaceutical and biotech ... of making money from selling healthcare products became increasingly apparent. George Merck addressed this question directly in 1950, proclaiming ...

In the US, healthcare costs and prices have been increasing. According to the Centers for Medicare & Medicaid Services, U.S.

Investors love dividend stocks, especially the high-yield variety, because they offer a significant income stream and have ...